Breast Implant Illness vs. BIA-ALCL: What Marketing Can Say

Explant and revision content is some of the highest-intent, most emotionally charged material a plastic surgery practice will ever publish — and it's also the material most likely to get a practice into trouble if it's imprecise. Two terms get conflated constantly in patient-facing marketing, and they describe genuinely different things.

BII: a reported symptom cluster, not a diagnosis

Breast implant illness refers to a range of symptoms patients have reported after receiving implants — commonly fatigue, brain fog, joint and muscle pain, and rash. It is not currently a recognized medical diagnosis, and there's no standardized test that confirms it. That doesn't mean the symptoms aren't real to the patients reporting them — it means marketing copy has to describe this as a patient-reported experience, not a medically confirmed condition with implants as a proven cause.

BIA-ALCL: a real, FDA-recognized diagnosis

Breast implant-associated anaplastic large cell lymphoma is a different matter entirely — a rare but serious T-cell non-Hodgkin lymphoma associated specifically with certain textured breast implants. It's a genuine cancer diagnosis with real epidemiological data behind it. Most cases are treated successfully with surgical removal of the implant and surrounding scar tissue, though some patients need chemotherapy or radiation, particularly if it isn't caught early. Since November 2021, the FDA has required implant manufacturers to include a patient decision checklist disclosing known and reported risks with every device.

Why the distinction matters for marketing specifically

• BII copy should stay in patient-experience language: "patients have reported...", "some patients describe symptom improvement after explant..." — never "implants cause BII" or "BII is diagnosed by..." as if standardized criteria exist.
• BIA-ALCL copy can reference it as a real, recognized diagnosis, but should stay factual and avoid fear-based framing that implies every implant carries the same risk — the association is specific to certain textured implant types, not implants generally.
• Never let the two blur together in the same sentence or claim — "implant illness and lymphoma risk" as a single undifferentiated hazard is inaccurate and is exactly the kind of claim that draws scrutiny.
• Testimonial and before/after content describing a patient's explant experience should stick to what that patient reported and observed, not extrapolate it into a general causal claim about implants.

What this means for practices marketing explant and revision services

None of this makes explant and revision content off-limits — patients researching this decision are actively searching for exactly this kind of clear, honest explanation, and a practice that gets the distinction right builds real trust with a searcher who has usually already read a year's worth of forum posts and is wary of anything that sounds like a sales pitch. The practices that win this search category are the ones whose content reads as more careful and more accurate than what a patient finds on a forum, not less.